Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Status:
Completed
Trial end date:
2020-10-13
Target enrollment:
Participant gender:
Summary
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients
with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
However, it is not known if early administration of HDIVC could prevent progression to ARDS.
We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19)
subjects given early or late in the disease course and may reduce the risk of respiratory
failure requiring mechanical ventilation and development of ARDS along with reductions in
supplemental oxygen demand and inflammatory markers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hunter Holmes Mcguire Veteran Affairs Medical Center